Veronica J Alexander

发表

Targeting APOC3 in the familial chylomicronemia syndrome.

D. Gaudet, D. Brisson, K. Tremblay, 2014, The New England journal of medicine.

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Richard G. Lee, S. Crooke, M. Graham, 2013, Circulation research.

Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III

Xiaoke Yin, M. Mayr, S. Kiechl, 2017, Journal of the American College of Cardiology.

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

J. Witztum, E. Hurh, R. Geary, 2019, European heart journal.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

R. Santos, D. Blom, L. Hemphill, 2017, Journal of clinical lipidology.

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

D. Gaudet, J. Tardif, C. Ballantyne, 2022, European heart journal.

Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOCIII.

M. Mayr, S. Kiechl, P. Willeit, 2017 .

ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance[S]

Christian M. Metallo, R. Krauss, C. Benner, 2019, Journal of Lipid Research.

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.

D. Gaudet, S. Freedman, D. Blom, 2019, The New England journal of medicine.